Literature DB >> 9687411

Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.

I Guillemin1, V Jarlier, E Cambau.   

Abstract

The in vitro activities of seven quinolones and the sequences of the quinolone resistance-determining regions (QRDR) in the A and B subunits of DNA gyrase were determined for 14 mycobacterial species. On the basis of quinolone activity, quinolones were arranged from that with the greatest to that with the least activity as follows: sparfloxacin, levofloxacin, ciprofloxacin, ofloxacin, pefloxacin, flumequine, and nalidixic acid. Based on MICs, the species could be organized into three groups: resistant (Mycobacterium avium, M. intracellulare, M. marinum, M. chelonae, M. abscessus [ofloxacin MICs, >/=8 microg/ml]), moderately susceptible (M. tuberculosis, M. bovis BCG, M. kansasii, M. leprae, M. fortuitum third biovariant, M. smegmatis [ofloxacin MICs, 0.5 to 1 microg/ml]), and susceptible (M. fortuitum, M. peregrinum, M. aurum [ofloxacin MICs, </=0.25 microg/ml]). Peptide sequences of the QRDR of GyrB were identical in all the species, including the amino acids at the three positions known to be involved in acquired resistance to quinolone, i.e., 426 (Asp), 447 (Arg), and 464 (Asn) (numbering system used for Escherichia coli). The last two residues could be involved in the overall low level of susceptibility of mycobacteria to quinolones since they differ from those found in the very susceptible E. coli (Lys-447 and Ser-464) but are identical to those found in the less susceptible Staphylococcus aureus and Streptococcus pneumoniae. Peptide sequences of the QRDR of GyrA were identical in all the species, except for the amino acid at position 83, which was an alanine in the two less susceptible groups and a serine in the most susceptible one, as in E. coli, suggesting that this amino acid is involved in the observed differences of quinolone susceptibility within the Mycobacterium genus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687411      PMCID: PMC105866     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Structure-activity relationships of the fluoroquinolones.

Authors:  D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory.

Authors:  P Kirschner; B Springer; U Vogel; A Meier; A Wrede; M Kiekenbeck; F C Bange; E C Böttger
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

Review 3.  Resistance to quinolones in mycobacteria.

Authors:  E Cambau; V Jarlier
Journal:  Res Microbiol       Date:  1996 Jan-Feb       Impact factor: 3.992

Review 4.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.

Authors:  B Ji; S Sow; E Perani; C Lienhardt; V Diderot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Structure and mechanism of DNA topoisomerase II.

Authors:  J M Berger; S J Gamblin; S C Harrison; J C Wang
Journal:  Nature       Date:  1996-01-18       Impact factor: 49.962

Review 7.  Mycobacterial cell wall: structure and role in natural resistance to antibiotics.

Authors:  V Jarlier; H Nikaido
Journal:  FEMS Microbiol Lett       Date:  1994-10-15       Impact factor: 2.742

Review 8.  The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.

Authors:  G J Alangaden; S A Lerner
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

9.  Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones.

Authors:  I Guillemin; E Cambau; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones.

Authors:  V Revel; E Cambau; V Jarlier; W Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more
  38 in total

1.  Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes.

Authors:  Jean-Noël Dauendorffer; Isabelle Guillemin; Alexandra Aubry; Chantal Truffot-Pernot; Wladimir Sougakoff; Vincent Jarlier; Emmanuelle Cambau
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

2.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Authors:  Areeya Disratthakit; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

4.  Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.

Authors:  D T Dubin; J E Fitzgibbon; M D Nahvi; J F John
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

5.  DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.

Authors:  M Maurin; C Abergel; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

Authors:  T Lu; X Zhao; X Li; A Drlica-Wagner; J Y Wang; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance.

Authors:  Hyun Kim; Chie Nakajima; Kazumasa Yokoyama; Zeaur Rahim; Youn Uck Kim; Hiroki Oguri; Yasuhiko Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

8.  Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.

Authors:  Aurélie Fillion; Alexandra Aubry; Florence Brossier; Aurélie Chauffour; Vincent Jarlier; Nicolas Veziris
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

9.  Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

Authors:  Nicolas Veziris; Chantal Truffot-Pernot; Alexandra Aubry; Vincent Jarlier; Nacer Lounis
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.

Authors:  Stéphanie Matrat; Alexandra Aubry; Claudine Mayer; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.